|
Tisagenlecleucel Clinical Trials
2 actively recruiting trials across 2 locations
Also known as: CART-19, CART19, CTL019, CTL019 T-cells, KYMRIAH, Kymriah, Tisagenlecleucel-T
Tucson, Arizona1 trial
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Banner University Medical Center - Tucson
Phase 2
Palo Alto, California1 trial
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.